Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TK1 | P04183 | 7/20 | 0.34 |
| ▸ | MMP13 | P45452 | 3/20 | 0.34 |
| ▸ | MMP10 | P09238 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12870959 | 0.84 | KMT2A (0.36) | KMT2ATK1MMP13MMP10 | |
| SCHEMBL24808855 | 0.80 | KMT2A (0.35) | KMT2AMAPTCYP2C9MMP13 | |
| SCHEMBL12870937 | 0.79 | KMT2A (0.36) | KMT2AMAPTCYP2C9MMP13MMP10 | |
| SCHEMBL12870914 | 0.76 | PGK1 (0.32) | — | |
| SCHEMBL24849610 | 0.72 | KMT2A (0.41) | KMT2AMMP13MMP10 | |
| SCHEMBL23957865 | 0.68 | KMT2A (0.33) | KMT2AMAPTCYP2C9 | |
| SCHEMBL6714052 | 0.67 | TK1 (0.57) | TK1 | |
| SCHEMBL29757418 | 0.66 | TK1 (0.58) | TK1 | |
| SCHEMBL12870950 | 0.66 | PKM (0.39) | KMT2AMMP13MMP10 | |
| SCHEMBL12870935 | 0.66 | KMT2A (0.33) | KMT2AMMP13MMP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028337-A1 | NUCLEOBASE CHARACTERISATION | NUCLEOBASE CHARACTERISATION | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028337-A1 | NUCLEOBASE CHARACTERISATION | NT5C3B, NT5C2, NT5E | KMT2A 1275/4885MAPT 3324/4885CYP2C9 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.